GB0716992D0 - Influenza antigen delivery vectors and constructs - Google Patents

Influenza antigen delivery vectors and constructs

Info

Publication number
GB0716992D0
GB0716992D0 GBGB0716992.3A GB0716992A GB0716992D0 GB 0716992 D0 GB0716992 D0 GB 0716992D0 GB 0716992 A GB0716992 A GB 0716992A GB 0716992 D0 GB0716992 D0 GB 0716992D0
Authority
GB
United Kingdom
Prior art keywords
constructs
delivery vectors
influenza antigen
antigen delivery
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0716992.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altimmune UK Ltd
Original Assignee
Immune Targeting Systems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38617093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0716992(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immune Targeting Systems Ltd filed Critical Immune Targeting Systems Ltd
Priority to GBGB0716992.3A priority Critical patent/GB0716992D0/en
Publication of GB0716992D0 publication Critical patent/GB0716992D0/en
Priority to HRP20140765AT priority patent/HRP20140765T1/hr
Priority to CN200880111908A priority patent/CN101827607A/zh
Priority to HK10110787.4A priority patent/HK1144153B/xx
Priority to ES08788477.1T priority patent/ES2488941T3/es
Priority to EA201070329A priority patent/EA018765B1/ru
Priority to KR1020167036184A priority patent/KR20170001729A/ko
Priority to US12/201,894 priority patent/US8642531B2/en
Priority to MX2010002335A priority patent/MX2010002335A/es
Priority to KR1020107006993A priority patent/KR101665141B1/ko
Priority to DK14160760.6T priority patent/DK2762164T3/da
Priority to JP2010522440A priority patent/JP5756630B2/ja
Priority to SI200831254T priority patent/SI2190474T1/sl
Priority to EP14160760.6A priority patent/EP2762164B1/en
Priority to CA2697729A priority patent/CA2697729C/en
Priority to EP08788477.1A priority patent/EP2190474B1/en
Priority to PCT/GB2008/002930 priority patent/WO2009027688A1/en
Priority to BRPI0815836-3A2A priority patent/BRPI0815836A2/pt
Priority to PT87884771T priority patent/PT2190474E/pt
Priority to PL08788477T priority patent/PL2190474T3/pl
Priority to CL2008002559A priority patent/CL2008002559A1/es
Priority to KR1020157014046A priority patent/KR101736897B1/ko
Priority to GB1005395A priority patent/GB2465733B/en
Priority to AU2008291974A priority patent/AU2008291974B2/en
Priority to ES14160760T priority patent/ES2741729T3/es
Priority to DK08788477.1T priority patent/DK2190474T3/da
Priority to TW97133417A priority patent/TWI469790B/zh
Priority to ARP080103803A priority patent/AR068507A1/es
Priority to TW102127018A priority patent/TW201345551A/zh
Priority to JP2013123602A priority patent/JP2013241414A/ja
Priority to US14/139,293 priority patent/US9446143B2/en
Priority to CY20141100646T priority patent/CY1115598T1/el
Priority to JP2016041049A priority patent/JP2016155829A/ja
Priority to US15/242,682 priority patent/US10155049B2/en
Priority to JP2017250464A priority patent/JP6826027B2/ja
Priority to US16/186,558 priority patent/US20210316000A9/en
Priority to JP2020160511A priority patent/JP2021001216A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB0716992.3A 2004-04-13 2007-08-31 Influenza antigen delivery vectors and constructs Ceased GB0716992D0 (en)

Priority Applications (37)

Application Number Priority Date Filing Date Title
GBGB0716992.3A GB0716992D0 (en) 2007-08-31 2007-08-31 Influenza antigen delivery vectors and constructs
ES14160760T ES2741729T3 (es) 2007-08-31 2008-08-29 Vectores y construcciones de liberación de antígenos de virus de la gripe
DK08788477.1T DK2190474T3 (da) 2007-08-31 2008-08-29 Vektorer og konstrukter til afgivelse af influenza-antigener
BRPI0815836-3A2A BRPI0815836A2 (pt) 2007-08-31 2008-08-29 Construção de antígeno-vetor de fluorocarboneto, vetor de fluorocarboneto, composição farmacêutica, uso da construção, e, métodos de tratamento ou imunização, para estimular uma resposta imune, e para preparar uma resposta farmacêutica profilática ou terapêutica.
PL08788477T PL2190474T3 (pl) 2007-08-31 2008-08-29 Wektory i konstrukty do dostarczania antygenu grypy
HK10110787.4A HK1144153B (en) 2007-08-31 2008-08-29 Influenza antigen delivery vectors and constructs
ES08788477.1T ES2488941T3 (es) 2007-08-31 2008-08-29 Vectores y constructos de liberación de antígenos de virus de la gripe
EA201070329A EA018765B1 (ru) 2007-08-31 2008-08-29 Векторы и конструкции для доставки гриппозного антигена
KR1020157014046A KR101736897B1 (ko) 2007-08-31 2008-08-29 인플루엔자 항원 수송 벡터 및 구조물
US12/201,894 US8642531B2 (en) 2004-04-13 2008-08-29 Influenza antigen delivery vectors and constructs
MX2010002335A MX2010002335A (es) 2007-08-31 2008-08-29 Vectores y construcciones de distribucion de antigeno de la influenza.
KR1020107006993A KR101665141B1 (ko) 2007-08-31 2008-08-29 인플루엔자 항원 수송 벡터 및 구조물
DK14160760.6T DK2762164T3 (da) 2007-08-31 2008-08-29 Influenzaantigen-indgivelsesvektorer og konstrukter
JP2010522440A JP5756630B2 (ja) 2007-08-31 2008-08-29 インフルエンザ抗原送達用のベクターおよび構築体
SI200831254T SI2190474T1 (sl) 2007-08-31 2008-08-29 Vektorji in konstrukti za dovajanje influenčnega antigena
EP14160760.6A EP2762164B1 (en) 2007-08-31 2008-08-29 Influenza antigen delivery vectors and constructs
CA2697729A CA2697729C (en) 2007-08-31 2008-08-29 Influenza antigen delivery vectors and constructs
EP08788477.1A EP2190474B1 (en) 2007-08-31 2008-08-29 Influenza antigen delivery vectors and constructs
PCT/GB2008/002930 WO2009027688A1 (en) 2007-08-31 2008-08-29 Influenza antigen delivery vectors and constructs
HRP20140765AT HRP20140765T1 (hr) 2007-08-31 2008-08-29 Vektori i konstrukti za prijenos antigena gripe
PT87884771T PT2190474E (pt) 2007-08-31 2008-08-29 Vectores e construções de distribuição de antigénios de influenza
CL2008002559A CL2008002559A1 (es) 2007-08-31 2008-08-29 Construccion que comprende un vector de fluorocarbono y un antigeno del virus de la influenza; composicion farmaceutica que lo comprende; y su uso para aumentar la respuesta inmunologica
CN200880111908A CN101827607A (zh) 2007-08-31 2008-08-29 流感病毒抗原送递载体和构建体
KR1020167036184A KR20170001729A (ko) 2007-08-31 2008-08-29 인플루엔자 항원 수송 벡터 및 구조물
GB1005395A GB2465733B (en) 2007-08-31 2008-08-29 Influenza antigen delivery vectors and constructs
AU2008291974A AU2008291974B2 (en) 2007-08-31 2008-08-29 Influenza antigen delivery vectors and constructs
TW102127018A TW201345551A (zh) 2007-08-31 2008-09-01 流行性感冒抗原遞送載體和構築體
ARP080103803A AR068507A1 (es) 2007-08-31 2008-09-01 Construcciones vector fluorocarbonado-antigeno para el suministro de antigenos ifluenza
TW97133417A TWI469790B (zh) 2007-08-31 2008-09-01 流行性感冒抗原遞送載體和構築體
JP2013123602A JP2013241414A (ja) 2007-08-31 2013-06-12 インフルエンザ抗原送達用のベクターおよび構築体
US14/139,293 US9446143B2 (en) 2007-08-31 2013-12-23 Influenza antigen delivery vectors and constructs
CY20141100646T CY1115598T1 (el) 2007-08-31 2014-08-13 Φορεις απελευθερωσης αντιγονου γριπης και κατασκευασματα
JP2016041049A JP2016155829A (ja) 2007-08-31 2016-03-03 インフルエンザ抗原送達用のベクターおよび構築体
US15/242,682 US10155049B2 (en) 2007-08-31 2016-08-22 Influenza antigen delivery vectors and constructs
JP2017250464A JP6826027B2 (ja) 2007-08-31 2017-12-27 インフルエンザ抗原送達用のベクターおよび構築体
US16/186,558 US20210316000A9 (en) 2007-08-31 2018-11-11 Influenza antigen delivery vectors and constructs
JP2020160511A JP2021001216A (ja) 2007-08-31 2020-09-25 インフルエンザ抗原送達用のベクターおよび構築体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0716992.3A GB0716992D0 (en) 2007-08-31 2007-08-31 Influenza antigen delivery vectors and constructs

Publications (1)

Publication Number Publication Date
GB0716992D0 true GB0716992D0 (en) 2007-10-10

Family

ID=38617093

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0716992.3A Ceased GB0716992D0 (en) 2004-04-13 2007-08-31 Influenza antigen delivery vectors and constructs
GB1005395A Expired - Fee Related GB2465733B (en) 2007-08-31 2008-08-29 Influenza antigen delivery vectors and constructs

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1005395A Expired - Fee Related GB2465733B (en) 2007-08-31 2008-08-29 Influenza antigen delivery vectors and constructs

Country Status (22)

Country Link
US (4) US8642531B2 (enExample)
EP (2) EP2190474B1 (enExample)
JP (5) JP5756630B2 (enExample)
KR (3) KR101736897B1 (enExample)
CN (1) CN101827607A (enExample)
AR (1) AR068507A1 (enExample)
AU (1) AU2008291974B2 (enExample)
BR (1) BRPI0815836A2 (enExample)
CA (1) CA2697729C (enExample)
CL (1) CL2008002559A1 (enExample)
CY (1) CY1115598T1 (enExample)
DK (2) DK2190474T3 (enExample)
EA (1) EA018765B1 (enExample)
ES (2) ES2488941T3 (enExample)
GB (2) GB0716992D0 (enExample)
HR (1) HRP20140765T1 (enExample)
MX (1) MX2010002335A (enExample)
PL (1) PL2190474T3 (enExample)
PT (1) PT2190474E (enExample)
SI (1) SI2190474T1 (enExample)
TW (2) TW201345551A (enExample)
WO (1) WO2009027688A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
WO2009129227A1 (en) 2008-04-17 2009-10-22 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
US20110165037A1 (en) * 2010-01-07 2011-07-07 Ismagilov Rustem F Interfaces that eliminate non-specific adsorption, and introduce specific interactions
JP2013540425A (ja) 2010-08-03 2013-11-07 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション インフルエンザ感染の治療および制限のうち少なくとも一方を行うためのポリペプチド
CN103282375B (zh) 2010-12-02 2017-01-11 比奥诺尔免疫有限公司 肽支架设计
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
CN102133396B (zh) * 2011-03-16 2013-10-16 中国人民解放军第三〇二医院 一种疫苗注射剂及其制备方法
WO2013093514A2 (en) * 2011-12-23 2013-06-27 Retroscreen Virology Ltd Vaccines - peptides
EP2800576A2 (en) 2012-03-13 2014-11-12 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
CN105163753B (zh) 2012-06-15 2018-12-21 Pds生物科技公司 阳离子脂质疫苗组合物和使用方法
EP2897639A4 (en) 2012-09-21 2016-05-04 Frank Bedu-Addo IMPROVED VACCINATE COMPOSITIONS AND METHODS OF USE
GB201321242D0 (en) 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
WO2015143339A2 (en) 2014-03-21 2015-09-24 University Of Washington Enhanced influenza hemagglutinin binders
WO2015157189A1 (en) * 2014-04-07 2015-10-15 The Regents Of The University Of California Vaccines and uses thereof
JP6103547B2 (ja) * 2015-01-09 2017-03-29 三菱電機株式会社 電子基板ユニット
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
EP3257864A1 (en) * 2016-06-16 2017-12-20 Université de Strasbourg Metabolically stable spexin peptide analogs
EP3257863A1 (en) * 2016-06-16 2017-12-20 Université de Strasbourg Flourous metabolically stable peptide analogs
CN110035765B (zh) * 2016-10-05 2024-04-02 Pds生物科技公司 新型hpv16非hla限制性t细胞疫苗、组合物及其使用方法
CN111148528A (zh) 2016-12-28 2020-05-12 英福瓦克思公司 流感疫苗
WO2019046901A1 (en) * 2017-09-08 2019-03-14 The University Of Melbourne METHODS AND COMPOSITIONS FOR PREVENTING INFLUENZA INFECTION
EP3773710A4 (en) * 2018-04-04 2022-03-16 Altimmune Inc COMBINATIONS OF VACCINE COMPOSITIONS INDUCING T LYMPHOCYTES AND THEIR USES
JP7037994B2 (ja) 2018-04-11 2022-03-17 株式会社シマノ 制御装置、人力駆動車、および制御方法
CN110772635B (zh) * 2019-11-11 2023-01-31 扬州大学 流感病毒小体包被的仿生纳米疫苗及其制备方法
EP4172897A1 (en) * 2020-06-29 2023-05-03 Seqirus UK Limited Adaptive vaccine stockpile
CN119306833B (zh) * 2023-07-11 2025-09-16 东莞市朋志生物科技有限公司 抗降钙素原抗体、检测降钙素原的试剂和试剂盒
CN117430664B (zh) * 2023-10-24 2024-04-09 暨南大学附属第六医院(东莞市东部中心医院) 一种甲型流感病毒t细胞抗原表位肽及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065141A (en) * 1960-08-24 1962-11-20 Albert E Gessler Separation of nucleoproteins and nucleic acids from aqueous protein mixtures
GB1193378A (en) 1967-04-11 1970-05-28 Rand Dev Corp Cancer Antigen Complexes
US3843443A (en) * 1973-03-30 1974-10-22 J Fishman Polypeptide materials bound to fluorocarbon polymers
US4332787A (en) * 1980-06-23 1982-06-01 The Massachusetts General Hospital Assay for beta-adrenergic antagonists and antibody therefor
US4689398A (en) * 1984-06-20 1987-08-25 Ortho Diagnostic Systems Inc. HTLV test using synthetic peptides
US4716102A (en) * 1984-08-15 1987-12-29 Regents Of The University Of California Purified AIDS-associated virus ARV-2
DE3782867D1 (en) * 1986-06-12 1993-01-14 Behringwerke Ag, 3550 Marburg, De Human cytomegalovirus phospho-protein
EP0257758B1 (en) * 1986-08-07 1993-03-10 Minnesota Mining And Manufacturing Company Stable biologically active fluorochemical emulsions
US4954444A (en) 1987-03-02 1990-09-04 E. I. Du Pont De Nemours And Company Enzyme immobilization and bioaffinity separations with perfluorocarbon polymer-based supports
US5055562A (en) * 1988-02-01 1991-10-08 Biomira, Inc. Fluorocarbon chain-containing antigenic conjugates
US5021551A (en) * 1989-01-18 1991-06-04 Washington University Method of enhancing peptide immunogenicity
US6413516B1 (en) * 1989-03-21 2002-07-02 The Immune Response Corporation Peptides and methods against psoriasis
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5817318A (en) * 1989-05-03 1998-10-06 Connaught Laboratories Limited Synthetic peptides for an HIV-1 vaccine
EP0529007A1 (en) * 1990-04-18 1993-03-03 The Regents Of The University Of California A 35kD TUMOR ASSOCIATED PROTEIN ANTIGEN: USES AND METHODS OF DETECTION
ATE194657T1 (de) * 1990-09-25 2000-07-15 Cantab Pharma Res Bei einer transkomplementenden zellinie erzeugter defektiver virenimpfstoff
US5871746A (en) * 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
JPH07500483A (ja) * 1991-03-14 1995-01-19 ブリティッシュ・テクノロジー・グループ・ユーエスエイ・インコーポレーテッド 組換え体抗コクシジアワクチン
EP0503203A1 (en) 1991-03-15 1992-09-16 Merrell Dow Pharmaceuticals Inc. Novel thrombin inhibitors
IL109664A0 (en) 1993-05-18 1994-08-26 Rijksuniversiteit Peptides of human influenza virus for use in human t cell response inducing compositions
DK0702563T3 (da) * 1993-05-27 2003-11-10 Entremed Inc Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme
US7344722B1 (en) * 1993-06-29 2008-03-18 The Regents Of The University Of Michigan Cold-adapted influenza virus
EP0756604A1 (en) * 1994-04-22 1997-02-05 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Melanoma antigens
GB9420146D0 (en) * 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
US6548046B1 (en) * 1995-06-08 2003-04-15 Barnes-Jewish Hospital Site specific binding system, imaging compositions and methods
US6069232A (en) * 1995-10-02 2000-05-30 Hoechst Marion Roussel, Inc. Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US6884414B1 (en) 1997-04-30 2005-04-26 Mount Sinai School Of Medicine Of New York University Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
US6121123A (en) 1997-09-05 2000-09-19 Advanced Micro Devices, Inc. Gate pattern formation using a BARC as a hardmask
AU1117999A (en) 1997-10-24 1999-05-17 Alliance Pharmaceutical Corporation Amelioration of ischemic damage using synthetic oxygen carriers
JP2002507397A (ja) 1998-03-13 2002-03-12 エピミューン，インコーポレイティド Ｈｌａ結合ペプチド及びその使用
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
CA2370413A1 (en) 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
FR2806727A1 (fr) 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
ATE536187T1 (de) 2000-10-19 2011-12-15 Epimmune Inc Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen
US6676963B1 (en) * 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
RU2218175C2 (ru) * 2001-03-06 2003-12-10 Научно-исследовательский институт по изучению лепры Способ стимуляции образования антител при иммунизации лабораторных животных
AU2002257647A1 (en) 2001-03-09 2002-09-24 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
EP1578432A4 (en) 2002-10-03 2008-07-30 Epimmune Inc HLA BINDING PEPTIDES AND USES THEREOF
US20050013826A1 (en) 2002-12-20 2005-01-20 Shneider Alexander M. Vaccine compositions and methods
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
EP1722819B1 (en) 2004-03-12 2007-12-26 Intercell AG Method for solubilising peptide mixtures
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
CN101116057B (zh) 2004-12-30 2011-10-05 英特尔公司 在多个指令定序器上基于指令集的线程执行机制
FR2883563B1 (fr) 2005-03-24 2007-06-01 Ts Pharma Sarl Nouveaux vecteurs cationiques bolaformes hemifluorocarbones et leurs applications
HUE049580T2 (hu) * 2006-01-27 2020-09-28 Seqirus Uk Ltd Hemagglutinint és mátrixfehérjéket tartalmazó, influenza elleni oltóanyagok
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
WO2007091387A1 (ja) * 2006-02-07 2007-08-16 Nec Corporation Ｈｌａ結合性ペプチド、その前駆体、それをコードするｄｎａ断片および組み換えベクター
GB201022147D0 (en) 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation

Also Published As

Publication number Publication date
EP2762164A1 (en) 2014-08-06
US20170049898A1 (en) 2017-02-23
KR101736897B1 (ko) 2017-05-17
JP5756630B2 (ja) 2015-07-29
CA2697729A1 (en) 2009-03-05
KR20170001729A (ko) 2017-01-04
KR20150074182A (ko) 2015-07-01
TW200930400A (en) 2009-07-16
BRPI0815836A2 (pt) 2015-03-03
US20210316000A9 (en) 2021-10-14
JP2013241414A (ja) 2013-12-05
MX2010002335A (es) 2010-08-10
TWI469790B (zh) 2015-01-21
EP2190474B1 (en) 2014-05-14
JP6826027B2 (ja) 2021-02-03
KR20100067094A (ko) 2010-06-18
TW201345551A (zh) 2013-11-16
GB2465733B (en) 2010-12-01
HK1144153A1 (en) 2011-01-28
AU2008291974A1 (en) 2009-03-05
SI2190474T1 (sl) 2014-09-30
CA2697729C (en) 2016-07-26
JP2018076355A (ja) 2018-05-17
EP2762164B1 (en) 2019-05-08
US9446143B2 (en) 2016-09-20
JP2010537961A (ja) 2010-12-09
EP2190474A1 (en) 2010-06-02
KR101665141B1 (ko) 2016-10-25
ES2488941T3 (es) 2014-09-01
US20190142951A1 (en) 2019-05-16
AU2008291974B2 (en) 2012-06-28
PL2190474T3 (pl) 2014-11-28
US20140234356A1 (en) 2014-08-21
JP2021001216A (ja) 2021-01-07
CN101827607A (zh) 2010-09-08
US8642531B2 (en) 2014-02-04
DK2190474T3 (da) 2014-08-18
CL2008002559A1 (es) 2009-06-26
ES2741729T3 (es) 2020-02-12
US20090191233A1 (en) 2009-07-30
HRP20140765T1 (hr) 2014-09-12
GB2465733A (en) 2010-06-02
CY1115598T1 (el) 2017-01-04
DK2762164T3 (da) 2019-08-12
EA018765B1 (ru) 2013-10-30
JP2016155829A (ja) 2016-09-01
PT2190474E (pt) 2014-08-29
WO2009027688A1 (en) 2009-03-05
US10155049B2 (en) 2018-12-18
EA201070329A1 (ru) 2010-10-29
GB201005395D0 (en) 2010-05-12
AR068507A1 (es) 2009-11-18

Similar Documents

Publication Publication Date Title
GB2465733B (en) Influenza antigen delivery vectors and constructs
IL209091A0 (en) Lysosomal targeting peptides and uses thereof
GB0408164D0 (en) Antigen delivery vectors and constructs
GB2468232B (en) Antigen-bindng constructs
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
ZA201104497B (en) Peptide therapeutic conjugates and uses thereof
PT2294202E (pt) Antigénios gripais recombinantes solúveis
IL216731A (en) And antibodies against p95 – her2 and their uses
EP2193144A4 (en) ANTIBODIES TO FLAGELLIN AND APPLICATIONS THEREOF
IL211670A (en) Preparations containing therapeutic antibodies against steap-1
EP2379106A4 (en) ANTIGENS OF CHLAMYDIAS AND USES THEREOF
IL199622A0 (en) Foxp3 peptide vaccine
IL216626A0 (en) Albumin-amyloid peptide conjugates and uses thereof
EP2580231A4 (en) PEPTIDES, CONSTRUCTIONS AND USES THEREOF
IL211040A (en) Melanoma antigen peptide and uses
GB0818065D0 (en) Immunogenic peptides and uses thereof
IL213318A0 (en) C1orf59 peptides and vaccines including the same
IL214453A0 (en) Vangli peptides and vaccines including the same
IL220146A0 (en) Tmem22 peptides and vaccines including the same
TWI346557B (en) Adjuvant and vaccine includes the same
GB0823492D0 (en) Antigenic peptides and uses thereof
HK1177683A (en) Multivalent glycopeptide constructs and uses thereof
GB0816561D0 (en) Peptides and uses thereof
GB0800701D0 (en) F10 Polypeptides and uses thereof
GB0800502D0 (en) Peptides and their uses

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)